What is the projected market valuation for the Nucleic Acid-based Therapeutics Market in 2035?

The projected market valuation for the Nucleic Acid-based Therapeutics Market in 2035 is 974.03 USD Million. Read More

What was the overall market valuation for the Nucleic Acid-based Therapeutics Market in 2024?

The overall market valuation for the Nucleic Acid-based Therapeutics Market in 2024 was 624.72 USD Million. Read More

What is the expected CAGR for the Nucleic Acid-based Therapeutics Market from 2025 to 2035?

The expected CAGR for the Nucleic Acid-based Therapeutics Market during the forecast period 2025 - 2035 is 4.12%. Read More

Which companies are considered key players in the Nucleic Acid-based Therapeutics Market?

Key players in the Nucleic Acid-based Therapeutics Market include Moderna, BioNTech, Gilead Sciences, Amgen, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Sangamo Therapeutics, Ionis Pharmaceuticals, and CureVac. Read More

What are the main applications of Nucleic Acid-based Therapeutics?

The main applications of Nucleic Acid-based Therapeutics include Gene Therapy, Antisense Oligonucleotides, RNA Interference, CRISPR Technology, and Vaccines. Read More

How much is the Gene Therapy segment valued at in 2025?

The Gene Therapy segment is valued at approximately 250.0 USD Million in 2025. Read More

What is the valuation range for RNA-based Therapeutics in 2025?

The valuation range for RNA-based Therapeutics in 2025 is between 200.0 and 300.0 USD Million. Read More

What delivery methods are utilized in the Nucleic Acid-based Therapeutics Market?

Delivery methods in the Nucleic Acid-based Therapeutics Market include Viral Vectors, Lipid Nanoparticles, Electroporation, Microinjection, and Naked Nucleic Acids. Read More

What is the projected valuation for the Lipid Nanoparticles segment in 2025?

The projected valuation for the Lipid Nanoparticles segment in 2025 is between 200.0 and 300.0 USD Million. Read More

How does the market for Oligonucleotide Therapeutics compare to other segments?

The market for Oligonucleotide Therapeutics is valued between 150.0 and 250.0 USD Million, indicating a competitive position among other segments. Read More

Nucleic Acid-based Therapeutics Market

Nucleic Acid-Based Therapeutics Market Research Report By Therapeutic Type (Antisense Oligonucleotides, RNA Interference, Gene Therapy, CRISPR, DNA Vaccines), By Application (Oncology, Genetic Disorders, Infectious Diseases, Cardiovascular Diseases), By Route of Administration (Injectable, Oral, Topical), By End User (Hospitals, Research Institutions, Pharmaceutical Companies, Biotechnology Companies) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

4.12%

2024 Market Size

$ 624.72 Million

2035 Market Size

$ 974.03 Million

Pharmaceutical ● Updated May 2026 Report ID: MRFR/Pharma/2192-HCR | Pages: 200 | Author: Satyendra Maurya, Rahul Gotadki

Summary Table of Contents Segmentation Methodology Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Application (USD Million) | |
  1. 4.1.1 Gene Therapy | |
  2. 4.1.2 Antisense Oligonucleotides | |
  3. 4.1.3 RNA Interference | |
  4. 4.1.4 CRISPR Technology | |
  5. 4.1.5 Vaccines |
2. 4.2 Healthcare, BY Type (USD Million) | |
  1. 4.2.1 DNA-based Therapeutics | |
  2. 4.2.2 RNA-based Therapeutics | |
  3. 4.2.3 Oligonucleotide Therapeutics | |
  4. 4.2.4 Gene Editing Technologies |
3. 4.3 Healthcare, BY Delivery Method (USD Million) | |
  1. 4.3.1 Viral Vectors | |
  2. 4.3.2 Lipid Nanoparticles | |
  3. 4.3.3 Electroporation | |
  4. 4.3.4 Microinjection | |
  5. 4.3.5 Naked Nucleic Acids |
4. 4.4 Healthcare, BY Region (USD Million) | |
  1. 4.4.1 North America | | |
    1. 4.4.1.1 US | | |
    2. 4.4.1.2 Canada | |
  2. 4.4.2 Europe | | |
    1. 4.4.2.1 Germany | | |
    2. 4.4.2.2 UK | | |
    3. 4.4.2.3 France | | |
    4. 4.4.2.4 Russia | | |
    5. 4.4.2.5 Italy | | |
    6. 4.4.2.6 Spain | | |
    7. 4.4.2.7 Rest of Europe | |
  3. 4.4.3 APAC | | |
    1. 4.4.3.1 China | | |
    2. 4.4.3.2 India | | |
    3. 4.4.3.3 Japan | | |
    4. 4.4.3.4 South Korea | | |
    5. 4.4.3.5 Malaysia | | |
    6. 4.4.3.6 Thailand | | |
    7. 4.4.3.7 Indonesia | | |
    8. 4.4.3.8 Rest of APAC | |
  4. 4.4.4 South America | | |
    1. 4.4.4.1 Brazil | | |
    2. 4.4.4.2 Mexico | | |
    3. 4.4.4.3 Argentina | | |
    4. 4.4.4.4 Rest of South America | |
  5. 4.4.5 MEA | | |
    1. 4.4.5.1 GCC Countries | | |
    2. 4.4.5.2 South Africa | | |
    3. 4.4.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Moderna (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 BioNTech (DE) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Gilead Sciences (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Amgen (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Regeneron Pharmaceuticals (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Vertex Pharmaceuticals (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Sangamo Therapeutics (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Ionis Pharmaceuticals (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 CureVac (DE) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY APPLICATION |
7. 6.4 US MARKET ANALYSIS BY TYPE |
8. 6.5 US MARKET ANALYSIS BY DELIVERY METHOD |
9. 6.6 CANADA MARKET ANALYSIS BY APPLICATION |
10. 6.7 CANADA MARKET ANALYSIS BY TYPE |
11. 6.8 CANADA MARKET ANALYSIS BY DELIVERY METHOD |
12. 6.9 EUROPE MARKET ANALYSIS |
13. 6.10 GERMANY MARKET ANALYSIS BY APPLICATION |
14. 6.11 GERMANY MARKET ANALYSIS BY TYPE |
15. 6.12 GERMANY MARKET ANALYSIS BY DELIVERY METHOD |
16. 6.13 UK MARKET ANALYSIS BY APPLICATION |
17. 6.14 UK MARKET ANALYSIS BY TYPE |
18. 6.15 UK MARKET ANALYSIS BY DELIVERY METHOD |
19. 6.16 FRANCE MARKET ANALYSIS BY APPLICATION |
20. 6.17 FRANCE MARKET ANALYSIS BY TYPE |
21. 6.18 FRANCE MARKET ANALYSIS BY DELIVERY METHOD |
22. 6.19 RUSSIA MARKET ANALYSIS BY APPLICATION |
23. 6.20 RUSSIA MARKET ANALYSIS BY TYPE |
24. 6.21 RUSSIA MARKET ANALYSIS BY DELIVERY METHOD |
25. 6.22 ITALY MARKET ANALYSIS BY APPLICATION |
26. 6.23 ITALY MARKET ANALYSIS BY TYPE |
27. 6.24 ITALY MARKET ANALYSIS BY DELIVERY METHOD |
28. 6.25 SPAIN MARKET ANALYSIS BY APPLICATION |
29. 6.26 SPAIN MARKET ANALYSIS BY TYPE |
30. 6.27 SPAIN MARKET ANALYSIS BY DELIVERY METHOD |
31. 6.28 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
32. 6.29 REST OF EUROPE MARKET ANALYSIS BY TYPE |
33. 6.30 REST OF EUROPE MARKET ANALYSIS BY DELIVERY METHOD |
34. 6.31 APAC MARKET ANALYSIS |
35. 6.32 CHINA MARKET ANALYSIS BY APPLICATION |
36. 6.33 CHINA MARKET ANALYSIS BY TYPE |
37. 6.34 CHINA MARKET ANALYSIS BY DELIVERY METHOD |
38. 6.35 INDIA MARKET ANALYSIS BY APPLICATION |
39. 6.36 INDIA MARKET ANALYSIS BY TYPE |
40. 6.37 INDIA MARKET ANALYSIS BY DELIVERY METHOD |
41. 6.38 JAPAN MARKET ANALYSIS BY APPLICATION |
42. 6.39 JAPAN MARKET ANALYSIS BY TYPE |
43. 6.40 JAPAN MARKET ANALYSIS BY DELIVERY METHOD |
44. 6.41 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
45. 6.42 SOUTH KOREA MARKET ANALYSIS BY TYPE |
46. 6.43 SOUTH KOREA MARKET ANALYSIS BY DELIVERY METHOD |
47. 6.44 MALAYSIA MARKET ANALYSIS BY APPLICATION |
48. 6.45 MALAYSIA MARKET ANALYSIS BY TYPE |
49. 6.46 MALAYSIA MARKET ANALYSIS BY DELIVERY METHOD |
50. 6.47 THAILAND MARKET ANALYSIS BY APPLICATION |
51. 6.48 THAILAND MARKET ANALYSIS BY TYPE |
52. 6.49 THAILAND MARKET ANALYSIS BY DELIVERY METHOD |
53. 6.50 INDONESIA MARKET ANALYSIS BY APPLICATION |
54. 6.51 INDONESIA MARKET ANALYSIS BY TYPE |
55. 6.52 INDONESIA MARKET ANALYSIS BY DELIVERY METHOD |
56. 6.53 REST OF APAC MARKET ANALYSIS BY APPLICATION |
57. 6.54 REST OF APAC MARKET ANALYSIS BY TYPE |
58. 6.55 REST OF APAC MARKET ANALYSIS BY DELIVERY METHOD |
59. 6.56 SOUTH AMERICA MARKET ANALYSIS |
60. 6.57 BRAZIL MARKET ANALYSIS BY APPLICATION |
61. 6.58 BRAZIL MARKET ANALYSIS BY TYPE |
62. 6.59 BRAZIL MARKET ANALYSIS BY DELIVERY METHOD |
63. 6.60 MEXICO MARKET ANALYSIS BY APPLICATION |
64. 6.61 MEXICO MARKET ANALYSIS BY TYPE |
65. 6.62 MEXICO MARKET ANALYSIS BY DELIVERY METHOD |
66. 6.63 ARGENTINA MARKET ANALYSIS BY APPLICATION |
67. 6.64 ARGENTINA MARKET ANALYSIS BY TYPE |
68. 6.65 ARGENTINA MARKET ANALYSIS BY DELIVERY METHOD |
69. 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
70. 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE |
71. 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY DELIVERY METHOD |
72. 6.69 MEA MARKET ANALYSIS |
73. 6.70 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
74. 6.71 GCC COUNTRIES MARKET ANALYSIS BY TYPE |
75. 6.72 GCC COUNTRIES MARKET ANALYSIS BY DELIVERY METHOD |
76. 6.73 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
77. 6.74 SOUTH AFRICA MARKET ANALYSIS BY TYPE |
78. 6.75 SOUTH AFRICA MARKET ANALYSIS BY DELIVERY METHOD |
79. 6.76 REST OF MEA MARKET ANALYSIS BY APPLICATION |
80. 6.77 REST OF MEA MARKET ANALYSIS BY TYPE |
81. 6.78 REST OF MEA MARKET ANALYSIS BY DELIVERY METHOD |
82. 6.79 KEY BUYING CRITERIA OF HEALTHCARE |
83. 6.80 RESEARCH PROCESS OF MRFR |
84. 6.81 DRO ANALYSIS OF HEALTHCARE |
85. 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
86. 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
87. 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE |
88. 6.85 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
89. 6.86 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million) |
90. 6.87 HEALTHCARE, BY TYPE, 2024 (% SHARE) |
91. 6.88 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Million) |
92. 6.89 HEALTHCARE, BY DELIVERY METHOD, 2024 (% SHARE) |
93. 6.90 HEALTHCARE, BY DELIVERY METHOD, 2024 TO 2035 (USD Million) |
94. 6.91 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
95. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
96. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.2.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.2.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
97. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.3.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.3.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
98. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.4.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.4.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
99. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.5.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.5.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
100. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.6.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.6.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
101. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.7.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.7.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
102. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.8.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.8.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
103. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.9.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.9.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
104. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.10.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.10.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
105. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.11.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.11.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
106. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.12.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.12.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
107. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.13.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.13.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
108. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.14.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.14.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
109. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.15.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.15.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
110. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.16.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.16.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
111. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.17.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.17.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
112. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.18.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.18.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
113. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.19.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.19.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
114. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.20.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.20.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
115. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.21.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.21.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
116. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.22.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.22.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
117. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.23.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.23.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
118. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.24.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.24.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
119. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.25.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.25.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
120. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.26.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.26.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
121. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.27.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.27.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
122. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.28.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.28.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
123. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.29.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.29.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
124. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY APPLICATION, 2025-2035 (USD Million) | |
  2. 7.30.2 BY TYPE, 2025-2035 (USD Million) | |
  3. 7.30.3 BY DELIVERY METHOD, 2025-2035 (USD Million) |
125. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
126. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Nucleic Acid-based Therapeutics Market Segmentation

Nucleic Acid-based Therapeutics Market By Application (USD Million, 2025-2035)

Gene Therapy
Antisense Oligonucleotides
RNA Interference
CRISPR Nucleic Acid-based Therapeutics Market
Vaccines

Nucleic Acid-based Therapeutics Market By Type (USD Million, 2025-2035)

DNA-based Therapeutics
RNA-based Therapeutics
Oligonucleotide Therapeutics
Gene Editing Technologies

Nucleic Acid-based Therapeutics Market By Delivery Method (USD Million, 2025-2035)

Viral Vectors
Lipid Nanoparticles
Electroporation
Microinjection
Naked Nucleic Acids

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”